Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase.

Moyer JD, Barbacci EG, Iwata KK, Arnold L, Boman B, Cunningham A, DiOrio C, Doty J, Morin MJ, Moyer MP, Neveu M, Pollack VA, Pustilnik LR, Reynolds MM, Sloan D, Theleman A, Miller P.

Cancer Res. 1997 Nov 1;57(21):4838-48.

3.

Blockade of the epidermal growth factor receptor tyrosine kinase activity by quercetin and luteolin leads to growth inhibition and apoptosis of pancreatic tumor cells.

Lee LT, Huang YT, Hwang JJ, Lee PP, Ke FC, Nair MP, Kanadaswam C, Lee MT.

Anticancer Res. 2002 May-Jun;22(3):1615-27.

PMID:
12168845
4.

The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.

Rusnak DW, Lackey K, Affleck K, Wood ER, Alligood KJ, Rhodes N, Keith BR, Murray DM, Knight WB, Mullin RJ, Gilmer TM.

Mol Cancer Ther. 2001 Dec;1(2):85-94.

6.

Blockage of epidermal growth factor receptor by quinazoline tyrosine kinase inhibitors suppresses growth of human hepatocellular carcinoma.

Liu Y, Poon RT, Shao W, Sun X, Chen H, Kok TW, Fan ST.

Cancer Lett. 2007 Apr 8;248(1):32-40. Epub 2006 Jul 11.

PMID:
16837130
7.

AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.

Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J, Meyer T, Tang C, Wartmann M, Wood J, Caravatti G.

Cancer Res. 2004 Jul 15;64(14):4931-41.

8.

Expression of functional epidermal growth factor receptors in a human hematopoietic cell line.

Oval J, Hershberg R, Gansbacher B, Gilboa E, Schlessinger J, Taetle R.

Cancer Res. 1991 Jan 1;51(1):150-6.

9.

Reversible G(1) arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27(KIP1) independent of MAPK activity.

Busse D, Doughty RS, Ramsey TT, Russell WE, Price JO, Flanagan WM, Shawver LK, Arteaga CL.

J Biol Chem. 2000 Mar 10;275(10):6987-95.

10.

The biological and biochemical effects of CP-654577, a selective erbB2 kinase inhibitor, on human breast cancer cells.

Barbacci EG, Pustilnik LR, Rossi AM, Emerson E, Miller PE, Boscoe BP, Cox ED, Iwata KK, Jani JP, Provoncha K, Kath JC, Liu Z, Moyer JD.

Cancer Res. 2003 Aug 1;63(15):4450-9.

11.

Blockade of epidermal growth factor receptor signaling leads to inhibition of renal cell carcinoma growth in the bone of nude mice.

Weber KL, Doucet M, Price JE, Baker C, Kim SJ, Fidler IJ.

Cancer Res. 2003 Jun 1;63(11):2940-7.

12.

11,11'-dideoxy-verticillin: a natural compound possessing growth factor receptor tyrosine kinase-inhibitory effect with anti-tumor activity.

Zhang YX, Chen Y, Guo XN, Zhang XW, Zhao WM, Zhong L, Zhou J, Xi Y, Lin LP, Ding J.

Anticancer Drugs. 2005 Jun;16(5):515-24.

PMID:
15846117
13.
14.
16.

Lidocaine inhibits tyrosine kinase activity of the epidermal growth factor receptor and suppresses proliferation of corneal epithelial cells.

Hirata M, Sakaguchi M, Mochida C, Sotozono C, Kageyama K, Kuroda Y, Hirose M.

Anesthesiology. 2004 May;100(5):1206-10.

PMID:
15114219
17.

Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis.

Zhou Y, Li S, Hu YP, Wang J, Hauser J, Conway AN, Vinci MA, Humphrey L, Zborowska E, Willson JK, Brattain MG.

Cancer Res. 2006 Jan 1;66(1):404-11.

18.

EGF-dependent and independent programmed cell death pathways in NCI-H596 nonsmall cell lung cancer cells.

Lei W, Mayotte JE, Levitt ML.

Biochem Biophys Res Commun. 1998 Apr 28;245(3):939-45.

PMID:
9588219
19.

Aplidin induces apoptosis in human cancer cells via glutathione depletion and sustained activation of the epidermal growth factor receptor, Src, JNK, and p38 MAPK.

Cuadrado A, Garcia-Fernandez LF, Gonzalez L, Suarez Y, Losada A, Alcaide V, Martinez T, Fernandez-Sousa JM, Sanchez-Puelles JM, Munoz A.

J Biol Chem. 2003 Jan 3;278(1):241-50. Epub 2002 Oct 31.

20.

Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice.

Pollack VA, Savage DM, Baker DA, Tsaparikos KE, Sloan DE, Moyer JD, Barbacci EG, Pustilnik LR, Smolarek TA, Davis JA, Vaidya MP, Arnold LD, Doty JL, Iwata KK, Morin MJ.

J Pharmacol Exp Ther. 1999 Nov;291(2):739-48.

Supplemental Content

Support Center